Joel Edward Nelson

US Patent:

20130079241, Mar 28, 2013

Filed:

Sep 14, 2012

Appl. No.:

13/619556

Inventors:

Jianhua Luo - Wexford PA, US
George Konstantine Michalopoulos - Pittsburg PA, US
Joel Byron Nelson - Pittsburgh PA, US
Chi Song - New Haven CT, US
Chien-Cheng Tseng - Pittsburgh PA, US
Yanping Yu - Wexford PA, US

International Classification:

C12Q 1/68

US Classification:

506 9

Abstract:

The present invention relates to methods and compositions for diagnosing prostate cancer and/or determining whether a prostate cancer patient is at increased risk of suffering a relapse, or a rapid relapse, of his cancer. It is based, at least in part, on the results of a comprehensive genome analysis on 241 prostate cancer samples (104 prostate cancer, 85 matched bloods, 49 matched benign prostate tissues adjacent to cancer, and 3 cell lines) which indicate that (i) genome copy number variation (CNV) occurred in both cancer and non-cancer tissues, and (ii) CNV predicts prostate cancer progression.

US Patent:

20220290257, Sep 15, 2022

Filed:

May 23, 2022

Appl. No.:

17/751152

Inventors:

- Pittsburgh PA, US
Zhanghui CHEN - Huzhou City, CN
Yanping YU - Wexford PA, US
George MICHALOPOULOS - Pittsburgh PA, US
Joel B. NELSON - Pittsburgh PA, US

Assignee:

UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION - Pittsburgh PA

International Classification:

C12Q 1/6886
A61P 35/00
A61K 31/4545
A61K 31/5377
A61N 7/00
C12N 15/113

Abstract:

The present invention relates to methods of treating cancer patients carrying one or more specific fusion genes. It is based, at least in part, on the discovery that the protein encoded by the MAN2A1-FER fusion gene exhibits kinase activity and the use of tyrosine kinase inhibitors targeting MAN2A1-FER in a cancer other than prostate, for example hepatocellular cancer, led to dramatic improvement of survival of animals xenografted with the cancer.

US Patent:

20200032346, Jan 30, 2020

Filed:

May 30, 2019

Appl. No.:

16/427185

Inventors:

- Pittsburgh PA, US
Zhanghui CHEN - Huzhou City, CN
Yanping YU - Wexford PA, US
George MICHALOPOULOS - Pittsburgh PA, US
Joel B. NELSON - Pittsburgh PA, US

Assignee:

UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION - Pittsburgh PA

International Classification:

C12Q 1/6886
A61K 31/5377
A61K 31/4545
A61P 35/00
C12N 15/113
A61N 7/00

Abstract:

The present invention relates to methods of treating cancer patients carrying one or more specific fusion genes. It is based, at least in part, on the discovery that the protein encoded by the MAN2A1-FER fusion gene exhibits kinase activity and the use of tyrosine kinase inhibitors targeting MAN2A1-FER in a cancer other than prostate, for example hepatocellular cancer, led to dramatic improvement of survival of animals xenografted with the cancer.

US Patent:

20190360056, Nov 28, 2019

Filed:

May 29, 2019

Appl. No.:

16/425355

Inventors:

- Pittsburgh PA, US
Yangping Yu - Wexford PA, US
Joel B. Nelson - Pittsburgh PA, US
George Konstantine Michalopoulos - Pittsburgh PA, US
Chien-Cheng Tseng - Pittsburgh PA, US
Ying Ding - San Diego CA, US

Assignee:

UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION - Pittsburgh PA

International Classification:

C12Q 1/6886

Abstract:

The present invention relates to methods and compositions for determining whether a subject having prostate cancer is at greater risk of developing progressive disease, and methods of treating the subjects. It is based, at least in part, on the discovery that approximately 90% of men carrying at least one of the following fusion genes: TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67 and CCNH-C5orf30 experienced prostate cancer recurrence, metastases and/or prostate cancer-specific death after radical prostatectomy (each examples of “progressive prostate cancer”), while these outcomes occurred in only 36% of men not carrying any of these fusion genes. It is also based, at least in part, on the discovery that no patient studied survived five years without recurrence if their primary prostate cancer contained a TRMT11-GRIK2 or MTOR-TP53BP1 fusion gene. It is also based, at least in part, on the discovery that the protein encoded by the MAN2A1-FER fusion gene exhibits kinase activity.

US Patent:

20190282708, Sep 19, 2019

Filed:

May 30, 2019

Appl. No.:

16/427212

Inventors:

- Pittsburgh PA, US
Zhanghui Chen - Huzhou City, CN
Yanping Yu - Wexford PA, US
George Michalopoulos - Pittsburgh PA, US
Joel B. Nelson - Pittsburgh PA, US
Chien-Cheng Tseng - Pittsburgh PA, US

Assignee:

UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION - Pittsburgh PA

International Classification:

A61K 48/00
A61P 35/00
C12Q 1/6886
C12N 15/11
C12N 9/22
A61K 31/522
A61K 38/46
A61K 31/7088

Abstract:

The present invention relates to methods for treating patients having cancer or a premalignant or neoplastic condition. It is based, at least in part, on the discovery that a genome editing technique that specifically targets a fusion gene can induce cell death in a cancer cell other than a prostate cancer cell, e.g., a hepatocellular cancer cell, having the fusion gene. The present invention provides methods for treating cancer patients that include performing a genome editing technique targeting a fusion gene present within one or more cells of a subject to produce an anti-cancer effect.

US Patent:

20190203231, Jul 4, 2019

Filed:

Mar 18, 2019

Appl. No.:

16/356587

Inventors:

- Pittsburgh PA, US
Yanping Yu - Wexford PA, US
Zhanghui Chen - Hangzhou, CN
George Konstantine Michalopoulos - Pittsburgh PA, US
Joel Nelson - Pittsburgh PA, US

Assignee:

UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION - Pittsburgh PA

International Classification:

C12N 15/90
C12N 9/12
C12Q 1/6886
C12N 15/11
A61K 31/522
A61K 38/17
A61K 48/00
C12N 15/63
C12N 9/22

Abstract:

The present invention relates to methods for treating prostate cancer patients. It is based, at least in part, on the discovery that approximately 90% of men carrying at least one of the following fusion genes: TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67 and CCNH-C5orf30 experienced prostate cancer recurrence, metastases and/or prostate cancer-specific death after radical prostatectomy (each examples of “progressive prostate cancer”), while these outcomes occurred in only 36% of men not carrying any of these fusion genes. It is also based, at least in part, on the discovery that a genome editing technique that specifically targets a fusion gene can induce cell death in a cancer cell that carries the fusion gene.

US Patent:

20190071733, Mar 7, 2019

Filed:

Nov 9, 2018

Appl. No.:

16/185372

Inventors:

- Pittsburgh PA, US
Yangping Yu - Wexford PA, US
Joel B. Nelson - Pittsburgh PA, US
George Konstantine Michalopoulos - Pittsburgh PA, US
Chien-Cheng Tseng - Pittsburgh PA, US
Ying Ding - San Diego CA, US

Assignee:

UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION - Pittsburgh PA

International Classification:

C12Q 1/6886

Abstract:

The present invention relates to methods and compositions for determining whether a subject having prostate cancer is at greater risk of developing progressive disease, and methods of treating the subjects. It is based, at least in part, on the discovery that approximately 90% of men carrying at least one of the following fusion genes: TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67 and CCNH-05orf30 experienced prostate cancer recurrence, metastases and/or prostate cancer-specific death after radical prostatectomy (each examples of “progressive prostate cancer”), while these outcomes occurred in only 36% of men not carrying any of these fusion genes. It is also based, at least in part, on the discovery that no patient studied survived five years without recurrence if their primary prostate cancer contained a TRMT11-GRIK2 or MTOR-TP53BP1 fusion gene. It is also based, at least in part, on the discovery that the protein encoded by the MAN2A1-FER fusion gene exhibits kinase activity.

US Patent:

20190022093, Jan 24, 2019

Filed:

Sep 24, 2018

Appl. No.:

16/139950

Inventors:

- Pittsburgh PA, US
James K. Johnson - Pittsburgh PA, US
Erin M. Skoda - Columbia MD, US
Joel B. Nelson - Pittsburgh PA, US
Zhou Wang - Pittsburgh PA, US
Serene Tai - Pittsburgh PA, US
Keita Takubo - Pittsburgh PA, US
John Milligan - Pittsburgh PA, US

Assignee:

University of Pittsburgh - Of the Commonwealth System of Higher Education - Pittsburgh PA

International Classification:

A61K 31/504
A61K 31/4985
A61K 31/497
A61K 31/4439
A61K 31/401
A61K 31/407
A61K 31/167
A61K 31/122
A61K 31/47
A61K 9/00
A61P 35/00

Abstract:

A compound, or a pharmaceutically acceptable salt or ester thereof, according to formula I:wherein Ris aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a thio-containing group, or a seleno-containing group; Z is alkanediyl, substituted alkanediyl, cycloalkanediyl, or substituted cycloalkanediyl; Y is S, O, S(═O), —S(═O)(═O)—, or NR, wherein Ris H or alkyl; Ris alkanediyl, substituted alkanediyl, cycloalkanediyl, substituted cycloalkanediyl, alkadienyl, substituted alkadienyl, cycloalkenediyl, substituted cycloalkenediyl, alkatrienyl, substituted alkatrienyl; X is —C(═O)—, —S(═O)(═O)—, or —N(H)C(═O)—; Rincludes at least one divalent amino radical; Ris aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a thio-containing group, or a seleno-containing group; a, b, c, and d independently are 0 or 1.

Address:

629 N Carrier Pkwy, Grand Prairie, TX 75050

Phone:

9722637277

VIN:

2FMDK3KC5BBA56761

Make:

FORD

Model:

EDGE

Year:

2011